Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 3
2004 5
2005 9
2006 11
2007 4
2008 5
2009 8
2010 3
2011 5
2013 6
2014 3
2015 4
2016 4
2017 5
2018 5
2019 8
2020 17
2021 16
2022 23
2023 17
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

148 results

Results by year

Filters applied: . Clear all
Page 1
2D TiO2 nanosheets decorated via sphere-like BiVO4: a promising non-toxic material for liquid phase photocatalysis and bacterial eradication.
Hanif MB, Bacova J, Berezenko V, Zeng Y, Paluch E, Seniuk A, Khan MZ, Rauf S, Hussain I, Motlochova M, Plesch G, Monfort O, Capek J, Dworniczek E, Rousar T, Motola M. Hanif MB, et al. Among authors: hussain i. ChemSusChem. 2024 Apr 8:e202400027. doi: 10.1002/cssc.202400027. Online ahead of print. ChemSusChem. 2024. PMID: 38588020
Mo-based MXenes: Synthesis, properties, and applications.
Hussain I, Amara U, Bibi F, Hanan A, Lakhan MN, Soomro IA, Khan A, Shaheen I, Sajjad U, Mohana Rani G, Javed MS, Khan K, Hanif MB, Assiri MA, Sahoo S, Al Zoubi W, Mohapatra D, Zhang K. Hussain I, et al. Adv Colloid Interface Sci. 2024 Feb;324:103077. doi: 10.1016/j.cis.2023.103077. Epub 2024 Jan 4. Adv Colloid Interface Sci. 2024. PMID: 38219341 Review.
Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials.
Maurer M, Ensina LF, Gimenez-Arnau AM, Sussman G, Hide M, Saini S, Grattan C, Fomina D, Rigopoulos D, Berard F, Canonica GW, Rockmann H, Irani C, Szepietowski JC, Leflein J, Bernstein JA, Peter JG, Kulthanan K, Godse K, Ardusso L, Ukhanova O, Staubach P, Sinclair R, Gogate S, Thomsen SF, Tanus T, Ye YM, Burciu A, Barve A, Modi D, Scosyrev E, Hua E, Letzelter K, Varanasi V, Patekar M, Severin T; PEARL-1 and PEARL-2 trial investigators. Maurer M, et al. Lancet. 2024 Jan 13;403(10422):147-159. doi: 10.1016/S0140-6736(23)01684-7. Epub 2023 Nov 23. Lancet. 2024. PMID: 38008109 Clinical Trial.
148 results